Bank of America
FULC icon

Bank of America’s Fulcrum Therapeutics FULC Stock Holding History

Bank of America’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.82M Buy
1,043,029
+916,470
+724% +$5.57M ﹤0.01% 3766
2026
Q1 		$971K Sell
126,559
-104,618
-45% -$970K ﹤0.01% 4543
2025
Q4 		$2.61M Buy
231,177
+83,966
+57% +$854K ﹤0.01% 3857
2025
Q3 		$1.35M Buy
147,211
+101,222
+220% +$732K ﹤0.01% 5127
2025
Q2 		$316K Sell
45,989
-10,146
-18% -$54.3K ﹤0.01% 5956
2025
Q1 		$162K Sell
56,135
-35,731
-39% -$131K ﹤0.01% 6283
2024
Q4 		$432K Sell
91,866
-8,049
-8% -$29.7K ﹤0.01% 5659
2024
Q3 		$357K Buy
99,915
+30,029
+43% +$223K ﹤0.01% 5700
2024
Q2 		$433K Buy
69,886
+8,233
+13% +$62.4K ﹤0.01% 5430
2024
Q1 		$582K Sell
61,653
-125,819
-67% -$1.12M ﹤0.01% 5261
2023
Q4 		$1.27M Buy
187,472
+48,428
+35% +$215K ﹤0.01% 4809
2023
Q3 		$617K Buy
139,044
+6,806
+5% +$29.7K ﹤0.01% 5169
2023
Q2 		$436K Buy
132,238
+89,868
+212% +$264K ﹤0.01% 5365
2023
Q1 		$121K Sell
42,370
-15,263
-26% -$137K ﹤0.01% 6174
2022
Q4 		$420K Buy
57,633
+27,815
+93% +$181K ﹤0.01% 5509
2022
Q3 		$242K Sell
29,818
-73,849
-71% -$529K ﹤0.01% 5868
2022
Q2 		$508K Buy
103,667
+88,836
+599% +$868K ﹤0.01% 5420
2022
Q1 		$351K Sell
14,831
-13,133
-47% -$186K ﹤0.01% 6070
2021
Q4 		$495K Buy
27,964
+20,496
+274% +$406K ﹤0.01% 5875
2021
Q3 		$211K Sell
7,468
-2,809
-27% -$53.2K ﹤0.01% 6270
2021
Q2 		$108K Buy
10,277
+5,272
+105% +$53.3K ﹤0.01% 6479
2021
Q1 		$59K Sell
5,005
-11,967
-71% -$148K ﹤0.01% 6582
2020
Q4 		$199K Buy
16,972
+13,305
+363% +$150K ﹤0.01% 5600
2020
Q3 		$29K Sell
3,667
-12,665
-78% -$153K ﹤0.01% 6201
2020
Q2 		$298K Buy
16,332
+818
+5% +$12.9K ﹤0.01% 4985
2020
Q1 		$186K Buy
15,514
+13,665
+739% +$219K ﹤0.01% 5122
2019
Q4 		$31K Sell
1,849
-1,321
-42% -$12.6K ﹤0.01% 6401
2019
Q3 		$22K Buy
+3,170
New +$35.1K ﹤0.01% 6566

Other funds holding FULC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of America's FULC Position: Q2 2026 in Review

Bank of America increased its Fulcrum Therapeutics (FULC) stake by 724% in Q2 2026, buying an estimated $5.57M and bringing the position to 1,043,029 shares worth $3.82M. The position accounts for ﹤0.01% of the portfolio, ranked #3766.

Bank of America first reported a position in FULC in Q3 2019 and has held it in 28 quarters since. 155 funds tracked by Wall St. Rank hold FULC as of Q2 2026.

  • Bank of America held 1,043,029 shares of Fulcrum Therapeutics worth $3.82M as of Q2 2026.
  • Bank of America bought 916,470 Fulcrum Therapeutics shares in Q2 2026, an estimated $5.57M.
  • Fulcrum Therapeutics made up ﹤0.01% of Bank of America's portfolio in Q2 2026, its #3766 holding.
  • Bank of America first reported a position in Fulcrum Therapeutics in Q3 2019 and has held it in 28 quarters since.
  • 155 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2026.

Based on Bank of America's 13F filing for Q2 2026, filed 14 Aug 2026.